"Correction of the Growth Defect in Dwarf Mice with Nonautologous Microencapsulated Myoblasts - An Alternate Approach to Somatic Gene Therapy."

According to the authors' abstract of an article published in Human Gene Therapy, "Most of the currently approved human gene therapy protocols depend on genetic modification of autologous cells. We propose an alternate and potentially more cost-effective approach by implanting genetically modified 'universal' cell lines to deliver desired gene products to nonautologous recipients. The recombinant allogeneic cells are protected from rejection after implantation by enclosure within immune-protective alginate-poly-L-lysine-alginate microcapsules. The clinical efficacy of this strategy is now demonstrated by implanting microencapsulated allogeneic myoblasts engineered to secrete mouse...

Want to see the full article?

• Purchase this article for only $3.00